You can deploy this model and start earning money today!

csong97/
setfit-jnj-relevancy

Name: setfit-jnj-relevancy
Availability: InStock

setfit

safetensors

mpnet

sentence-transformers

text-classification

generated_from_setfit_trainer

2209.11055

sentence-transformers/paraphrase-mpnet-base-v2

finetune

model-index

Views

No views yet

SetFit with sentence-transformers/paraphrase-mpnet-base-v2

This is a SetFit model that can be used for Text Classification. This SetFit model uses sentence-transformers/paraphrase-mpnet-base-v2 as the Sentence Transformer embedding model. A LogisticRegression instance is used for classification.

The model has been trained using an efficient few-shot learning technique that involves:

Fine-tuning a Sentence Transformer with contrastive learning.
Training a classification head with features from the fine-tuned Sentence Transformer.

Model Details

Model Description

Model Type: SetFit
Sentence Transformer body: sentence-transformers/paraphrase-mpnet-base-v2
Classification head: a LogisticRegression instance
Maximum Sequence Length: 512 tokens
Number of Classes: 2 classes

Model Sources

Repository: SetFit on GitHub
Paper: Efficient Few-Shot Learning Without Prompts
Blogpost: SetFit: Efficient Few-Shot Learning Without Prompts

Model Labels

Label

Examples

'paradigmshifting new therapies are helping people with the disease lead longer more comfortable lives for bladder cancer awareness month learn how johnson johnson is helping to change the treatment landscape\n\nsome of the early signs of bladder cancer can be easy to dismiss lower back pain painful or frequent urination these can point to any number of benign conditions including urinary tract infection and kidney stones it’s the unsettling discovery of blood in the urine that sends most people with bladder cancer in search of medical advice\n\nbladder cancer is the ninth most common cancer worldwide about one in four cases is considered muscleinvasive bladder cancer mibc meaning the tumor has penetrated the bladder’s muscular wall or has spread outside the organ mibc is aggressive and typically requires radiation or complete removal of the bladder a procedure called a cystectomy at the time of first diagnosis most bladder cancers are nonmuscleinvasive they arise in the bladder lining and tend to respond well to a combination of surgery immunotherapy and chemotherapy\n\nimmunotherapy and chemotherapy are frequently delivered directly into the bladder although those treatments remain a mainstay of bladder cancer care today their effectiveness is limited a patient can hold these drugs in their bladder for only so long “after a few hours the patient voids the medication” explains chris cutie md vice president disease area leader bladder cancer johnson johnson innovative medicine\n\nresearchers at johnson johnson have come up with a novel investigational option to help address this problem a targeted releasing system that is placed in the bladder and stays there for weeks at a time continuously exposing urine and bladder tissue to therapy it’s just one of the new approaches the company is working on to improve the lives and longevity of patients with bladder cancer we spoke to dr cutie as well as sumeet bhanvadia md senior director johnson johnson innovative medicine to learn more about this disease and the new treatments that are changing the way patients fight it\n\n\nsmoking—as well as onthejob exposures—can raise your risk\nsmoking is the single biggest risk factor associated with bladder cancer in fact half of all bladder cancer cases can be linked to cigarette use it’s easy to see why after tobacco’s cancercausing substances carcinogens get absorbed into the bloodstream they’re filtered by the kidneys and then collect in the urine exposing the bladder to high levels of toxic chemicals which can damage the dna in the cells lining the bladder\n\nbladder cancer may actually be driven in some part and in some forms by androgen receptors\nchris cutie md\nvice president disease area leader bladder cancer johnson johnson innovative medicine\nbut cigarettes aren’t the only culprit exposure to other types of chemicals can also raise a person’s risk “people who work with hair dye in salons tend to have higher rates of bladder cancer” says dr cutie and those who work with the kinds of toxic dyes paints and solvents often used in heavy industry—like steelmaking—also face a higher chance of developing the disease\n\nmen carry a higher risk for developing bladder cancer than women and are three times more likely to get it used to be experts thought that was because more men smoke and work in industrial jobs but that thinking is changing dr cutie says research suggests that the gender disparity in bladder cancer rates may be partly attributable to hormones “it looks like bladder cancer may actually be driven in some part and in some forms by androgen receptors” dr cutie says referring to proteins on the surface of cells that bind to male hormones such as testosterone\n\nandrogen hormones and androgen receptors play a role in immune function to fight cancer—or any other disease or invader—healthy immune function is critical “when i was in medical school we were trained to look at the bladder as this simple storage organ and nothing more” dr cutie says “but that view has shifted we now know it’s also an immunogenic organ that plays an important role in immune recognition and immune signaling” researchers are still learning about the androgen receptor’s role in bladder cancer\n\n\nas with most cancers early diagnosis improves patient outcomes\ncurrently there is no recommended screening for bladder cancer but researchers are exploring whether it makes sense to screen highrisk groups like smokers and former smokers\n\ntransitional cell carcinoma micrographbladder cancer section\nmost bladder cancers are urothelial in origin also called transitionalcell because the cells change shape and arise on the surface of the cells that line the urinefacing side of the bladder among those most are nonmuscle invasive slowgrowing and highly treatable once the cancer enters the bladder muscle or spreads to lymph nodes or beyond however it becomes harder to treat dr cutie says\n\nchemotherapy can be effective but because many patients are older and have other health problems it isn’t always tolerable a cystectomy also requires creation of a urinary diversion made of intestine overall it’s a complex operation that carries significant risks for elderly people and one that has a significant impact on quality of life according to dr bhanvadia about of patients who have their bladder removed will suffer complications within the first few months of surgery “overall half of people with muscleinvasive bladder cancer will develop metastases within years even if they have received comprehensive treatments” she adds “whether cancerous cells are found in the lymph nodes at the time of surgery has the biggest impact on survival outcomes which is why early diagnosis has a huge impact on patient outcomes”\n\n\nyou can live with bladder cancer\ncaught early bladder cancer can be managed but it’s prone to recurring—which puts patients on the hook for followups for the rest of their lives “bladder cancer is currently incurable so patients have to be followed forever” says dr cutie “that means sending in periodic urine tests and having your bladder inspected every three months with a cystoscope or camera which is burdensome costly and uncomfortable”\n\nnot surprisingly a significant percentage of patients with bladder cancer suffer from mental health issues such as anxiety and depression “when you check these patients and say to them ‘hey i didn’t see anything on exam today’ they smile and give you a high five—and then they realize they need a followup appointment in three months” dr cutie says “you can see their faces fall”\n\n\nafter a long pause research is advancing fast\nin the mid s researchers made a big discovery bladder cancer appeared to respond to immunotherapy bcg short for bacille calmetteguerin a vaccine originally developed in the early s for tuberculosis could be altered in a way that helped the body’s immune system recognize and kill bladder cancer cells in bcg became the first immunotherapy for cancer approved by the fda for more than years it’s been the standard of care\n\nand yet following that historymaking advancement progress in the treatment of bladder cancer slowed to a crawl “for decades bladder cancer research was a wasteland” dr cutie says “there was very little innovation”\n\ntaking the chemotherapy agent and putting it into this innovative system that allows for continuous and lowdose delivery may improve effectiveness while at the same time minimizing side effects to the patient\nsumeet bhanvadia md\nsenior director johnson johnson innovative medicine\neven today latestage bladder cancer requires radical treatment with the removal of the bladder patients who undergo cystectomy must adapt to life after surgery with a urinary stoma a bag that collects urine outside of the body\n\ntreatments for earlierstage bladder cancer have been slow to evolve too bcg and chemotherapy have been used for decades traditionally patients received these therapies by having them injected through a tube placed into the bladder through the urethra a major limitation of this approach is that while these medications do have the capacity to kill these bladder cancer cells the medication is only in contact with malignant cells for a few hours limiting the effectiveness\n\ndr cutie and his colleagues knew there had to be a different way to deliver potent bladder cancer therapies based on results from ongoing clinical studies a version of the aforementioned targeted delivery system which allows low doses of chemotherapy to be released in the bladder slowly over weeks received breakthrough therapy designation from the fda for potential future use in patients with bcgunresponsive highrisk nonmuscleinvasive bladder cancer who are ineligible for or don’t want cystectomy\n\n“taking the chemotherapy agent that we know is effective against bladder cancer cells and putting it into this innovative system that allows for continuous and lowdose delivery may improve effectiveness while at the same time minimizing side effects to the patient” dr bhanvadia says “this could make a meaningful difference for patients”\n\n\ntreatments have come a long way—and they’re improving\nan approved systemic treatment for patients with advanced or metastatic urothelial cancer whose tumor has a specific abnormal gene works by blocking the activity of the gene in cancer cells and in healthy cells throughout the body “but treatments are only effective if they work and are also well tolerated” says dr bhanvadia as such researchers and physicianscientists at johnson johnson are also studying ways to administer this targeted medicine that may reduce side effects without compromising effectiveness this includes a targeted releasing system that delivers the drug directly into the bladder again with sustained slow delivery\n\nno two cancer patients have the same genetic profile and tailoring their treatment to their unique characteristics may improve their outcomes as the emerging field of precision medicine grows and as additional genespecific therapies become available patients will have more options that’s a huge win for patients says dr cutie'
'approval is based on results from the phase papillon study which demonstrated rybrevant® plus chemotherapy reduced the risk of disease progression or death by percent versus chemotherapy alone in patients with previously untreated nsclc with egfr exon insertion mutations\n\nnational comprehensive cancer network ® nccn ® updated its nccn clinical practice guidelines in oncology nccn guidelines ® to recommend amivantamabvmjw rybrevant® plus chemotherapy as a preferred firstline regimen for patients with nsclc with egfr exon insertion mutations\n\nraritan new jersey march – johnson johnson nyse jnj announced today that following a priority review the us food and drug administration fda has approved rybrevant® amivantamabvmjw in combination with chemotherapy carboplatinpemetrexed for the firstline treatment of patients with locally advanced or metastatic nonsmall cell lung cancer nsclc with epidermal growth factor receptor egfr exon insertion mutations as detected by an fdaapproved test this fda action converts the may accelerated approval of rybrevant® to a full approval based on the confirmatory phase papillon study\n\n“when aiming for the best possible treatment outcomes a targeted approach should be used in the first line for patients with egfr exon insertion mutations as this is a commonly applied practice for patients with nsclc harboring other molecular driver alterations” said joshua k sabari md an oncologist at nyu langone’s perlmutter cancer center and study investigator “the results observed in the papillon study showed significant improvement in progressionfree survival supporting the use of this regimen as the potential standardofcare in the firstline treatment of these patients”\n\nworldwide lung cancer is one of the most common cancers with nsclc making up to percent of all lung cancer cases alterations in egfr are the most common actionable driver mutations in nsclc clinical data show patients with egfr exon insertion mutations generally experience limited benefits with currently approved thirdgeneration egfr tyrosine kinase inhibitors and chemotherapy nsclc driven by egfr exon insertion mutations carries a worse prognosis and shorter survival rates compared with lung cancer driven by other egfr driver mutations\n\n“for patients with lung cancer and their families each breakthrough in treatment provides not only a new option but a potential lifeline the approval of rybrevant plus chemotherapy heralds a promising new firstline treatment option for patients newly diagnosed with nonsmall cell lung cancer where their driver mutation is an egfr exon insertion” said marcia horn executive director of the exon group and ceo of ican international cancer advocacy network “this new regimen is a major advance over chemotherapy alone we’ve seen firsthand the extended survival that exon group patients experienced on rybrevant plus chemotherapy in the papillon study and we’re delighted that this historic treatment option which specifically targets the egfr exon insertion mutation has been approved”\n\nthe fda approval is based on positive results from the randomized openlabel phase papillon study which showed rybrevant® plus chemotherapy resulted in a percent reduction in the risk of disease progression or death compared to chemotherapy alone results also showed treatment with rybrevant® plus chemotherapy improved objective response rate orr and progressionfree survival pfs based on papillon data the national comprehensive cancer network ® nccn ® updated its’ nccn clinical practice guidelines nccn guidelines® to include a category recommendation for amivantamabvmjw rybrevant® plus chemotherapy as a preferred firstline therapy for patients with nsclc with egfr exon insertion mutations †‡\n\n“we are redefining care for patients with nonsmall cell lung cancer by advancing innovative regimens that can be used early with the goal of extending survival” said kiran patel md vice president clinical development solid tumors johnson johnson innovative medicine “rybrevant plus chemotherapy is the first targeted approach approved for the firstline treatment of patients with nsclc with egfr exon insertion mutations we look forward to building on this latest milestone as we continue to accelerate our transformative lung cancer portfolio”\n\nwarnings and precautions include infusion related reactions irr interstitial lung disease ildpneumonitis dermatologic adverse reactions ocular toxicity and embryofetal toxicity the most common adverse reactions percent were rash nail toxicity stomatitis irr fatigue edema constipation decreased appetite nausea covid diarrhea and vomiting the most common grade or laboratory abnormalities percent were decreased albumin increased alanine aminotransferase increased gammaglutamyl transferase decreased sodium decreased potassium decreased magnesium and decreases in white blood cells hemoglobin neutrophils platelets and lymphocytes\n\nabout the papillon study\npapillon nct is a randomized openlabel phase study evaluating the efficacy and safety of rybrevant® in combination with chemotherapy compared with chemotherapy alone in newly diagnosed patients with advanced or metastatic nsclc characterized by egfr exon insertion mutations the primary endpoint of the study is pfs using recist v guidelines§ as assessed by blinded independent central review bicr secondary endpoints include orr pfs after first subsequent therapy time to symptomatic progression and overall survival os patients who received chemotherapy alone were allowed to receive rybrevant® monotherapy in the secondline setting after confirmation of disease progression\n\nabout rybrevant®\nrybrevant® amivantamabvmjw a fullyhuman bispecific antibody targeting egfr and met with immune celldirecting activity is approved in the us europe and in other markets around the world as monotherapy for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon insertion mutations as detected by an fdaapproved test whose disease has progressed on or after platinumbased chemotherapy this indication is approved under accelerated approval based on orr and duration of response dor continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials rybrevant® is also approved in the us in combination with chemotherapy carboplatin and pemetrexed for the firstline treatment of adult patients with locally advanced or metastatic nsclc with egfr exon insertion mutations as detected by an fdaapproved test in october a type ii extension of indication application was submitted to the european medicines agency ema seeking approval of rybrevant® for this indication in december johnson johnson submitted an sbla together with a new drug application nda to the us fda for rybrevant® in combination with lazertinib for the firstline treatment of adult patients with locally advanced or metastatic nsclc with egfr exon deletions or lr substitution mutations as detected by an fdaapproved test this submission is based on the phase mariposa study and was granted priority review in february a marketing authorization application maa and type ii extension of indication application were also submitted to the ema seeking approval of lazertinib in combination with rybrevant® based on the mariposa study in november johnson johnson submitted an sbla to the us fda for rybrevant® in combination with chemotherapy for the treatment of patients with egfrmutated nsclc who progressed on or after osimertinib based on the mariposa study a type ii extension of indication application was also submitted to the ema seeking the approval of rybrevant® for this indication\n\nthe nccn clinical practice guidelines in oncology nccn guidelines® for nsclc prefer nextgeneration sequencingbased strategies over polymerase chain reactionbased approaches for the detection of egfr exon insertion variants the nccn guidelines® include\n\namivantamabvmjw rybrevant® plus carboplatin and pemetrexed as a preferred category recommendation firstline therapy in treatmentnaive patients with newly diagnosed advanced or metastatic egfr exon insertion mutationpositive advanced nsclc or as a subsequent therapy option category a recommendation for patients that have progressed on or after platinumbased chemotherapy with or without immunotherapy and have egfr exon insertion mutationpositive advanced nsclc †‡\namivantamabvmjw rybrevant® plus chemotherapy as a preferred category recommendation subsequent therapy for patients with locally advanced or metastatic ncslc with egfr exon deletions or exon lr mutations who experienced disease progression after treatment with osimertinib †‡\namivantamabvmjw rybrevant® as a subsequent therapy option category a recommendation for patients that have progressed on or after platinumbased chemotherapy with or without an immunotherapy and have egfr exon insertion mutationpositive nsclc †‡\nin addition to the phase papillon study rybrevant® is being studied in multiple clinical trials in nsclc including\n\nthe phase mariposa nct study evaluating the efficacy and safety of rybrevant® and chemotherapy in patients with locally advanced or metastatic egfr exdel or lr substitution nsclc who had disease progression on or after treatment with osimertinib data for this randomized phase study presented at the esmo congress demonstrated statistically significant and clinically meaningful improvement in pfs in patients receiving rybrevant® plus chemotherapy with and without lazertinib versus chemotherapy\nthe phase mariposa nct study assessing rybrevant® in combination with lazertinib a novel thirdgeneration egfr tki versus osimertinib and versus lazertinib alone in the firstline treatment of patients with locally advanced or metastatic nsclc with egfr exon deletions exdel or lr substitution mutations data for this randomized phase study presented at the esmo congress showed statistically significant and clinically meaningful improvement in progressionfree survival in patients with egfrmutated advanced nsclc treated with rybrevant® plus lazertinib versus osimertinib\nthe phase chrysalis nct study evaluating rybrevant® in participants with advanced nsclc\nthe phase b chrysalis nct study evaluating rybrevant® in combination with lazertinib and lazertinib as a monotherapy in patients with advanced nsclc with egfr mutations\nthe phase paloma nct study assessing the feasibility of subcutaneous sc administration of amivantamab based on safety and pharmacokinetics and to determine a dose dose regimen and formulation for amivantamab sc delivery\nthe phase paloma nct study assessing subcutaneous amivantamab in participants with advanced or metastatic solid tumors including egfrmutated nsclc\nthe phase paloma nct study assessing lazertinib with subcutaneous amivantamab compared to intravenous amivantamab in participants with egfrmutated advanced or metastatic nsclc\nthe phase metalmark nct study assessing rybrevant® and capmatinib combination therapy in locally advanced or metastatic nsclc\nthe phase polydamas nct study assessing rybrevant® and cetrelimab combination therapy in locally advanced or metastatic nsclc\nthe phase skippirr study nct exploring how to decrease the incidence andor severity of firstdose infusionrelated reactions with rybrevant® in combination with lazertinib in relapsed or refractory egfrmutated advanced or metastatic nsclc\nthe phase cocoon study nct will evaluate enhanced dermatological care to reduce rash and paronychia in patients with egfrmutated nsclc treated firstline with amivantamab plus lazertinib\nfor more information visit \n\nabout nonsmall cell lung cancer\nworldwide lung cancer is one of the most common cancers with nsclc making up to percent of all lung cancer cases the main subtypes of nsclc are adenocarcinoma squamous cell carcinoma and large cell carcinoma among the most common driver mutations in nsclc are alterations in egfr which is a receptor tyrosine kinase controlling cell growth and division egfr mutations are present in to percent of western patients with nsclc with adenocarcinoma histology and occur in to percent of asian patients egfr exdel or egfr lr mutations are the most common egfr mutations the fiveyear survival rate for all people with advanced nsclc and egfr mutations treated with egfr tkis is less than percent patients with egfr exdel or lr mutations have a realworld fiveyear os of percent\n\nrybrevant® important safety information\n\nwarnings and precautions\nthe safety population of rybrevant® with carboplatin and pemetrexed described in warnings and precautions was based on patients in the papillon study\n\nthe safety population of rybrevant® as a single agent described in warnings and precautions was based on patients in the chrysalis study\n\ninfusionrelated reactions\nrybrevant® can cause infusionrelated reactions irr signs and symptoms of irr include dyspnea flushing fever chills nausea chest discomfort hypotension and vomiting\n\nrybrevant® with carboplatin and pemetrexed\n\nrybrevant in combination with carboplatin and pemetrexed can cause infusionrelated reactions based on the safety population infusionrelated reactions occurred in of patients treated with rybrevant® in combination with carboplatin and pemetrexed including grade adverse reactions the incidence of infusion modifications due to irr was and of patients permanently discontinued rybrevant\n\nrybrevant®as a single agent\n\nbased on the safety population irr occurred in of patients treated with rybrevant® among patients receiving treatment on week day experienced an irr while the incidence of irr was with the day infusion with the week infusion and cumulatively with subsequent infusions of the reported irrs were grade were grade and were grade the median time to onset was hour range to hours after start of infusion the incidence of infusion modifications due to irr was and of patients permanently discontinued rybrevant® due to irr\n\npremedicate with antihistamines antipyretics and glucocorticoids and infuse rybrevant® as recommended administer rybrevant® via a peripheral line on week and week monitor patients for any signs and symptoms of infusion reactions during rybrevant® infusion in a setting where cardiopulmonary resuscitation medication and equipment are available interrupt infusion if irr is suspected reduce the infusion rate or permanently discontinue rybrevant® based on severity\n\ninterstitial lung diseasepneumonitis\nrybrevant® can cause interstitial lung disease ildpneumonitis\n\nrybrevant® with carboplatin and pemetrexed\n\nbased on the safety population grade ildpneumonitis occurred in of patients treated with rybrevant® in combination with carboplatin and pemetrexed all patients required permanent discontinuation\n\nrybrevant® as a single agent\n\nbased on the safety population ildpneumonitis occurred in of patients treated with rybrevant® with of patients experiencing grade ildpneumonitis three patients discontinued rybrevant® due to ildpneumonitis\n\nmonitor patients for new or worsening symptoms indicative of ildpneumonitis eg dyspnea cough fever immediately withhold rybrevant® in patients with suspected ildpneumonitis and permanently discontinue if ildpneumonitis is confirmed\n\ndermatologic adverse reactions\nrybrevant® can cause rash including dermatitis acneiform pruritus and dry skin\n\nrybrevant®with carboplatin and pemetrexed\n\nrybrevant in combination with carboplatin and pemetrexed can cause dermatologic adverse reactions based on the safety population rash occurred in of patients treated with rybrevant® in combination with carboplatin and pemetrexed including grade adverse reactions rash leading to dose reductions occurred in of patients permanently discontinued rybrevant® and discontinued pemetrexed\n\nrybrevant® as a single agent\n\nbased on the safety population rash occurred in of patients treated with rybrevant® including grade rash in of patients the median time to onset of rash was days range to days rash leading to dose reduction occurred in of patients and rybrevant® was permanently discontinued due to rash in of patients\n\ntoxic epidermal necrolysis occurred in one patient treated with rybrevant® as a single agent\n\ninstruct patients to limit sun exposure during and for months after treatment with rybrevant® advise patients to wear protective clothing and use broadspectrum uvauvb sunscreen alcoholfree emollient cream is recommended for dry skin\n\nif skin reactions develop start topical corticosteroids and topical andor oral antibiotics for grade reactions add oral steroids and consider dermatologic consultation promptly refer patients presenting with severe rash atypical appearance or distribution or lack of improvement within weeks to a dermatologist withhold dose reduce or permanently discontinue rybrevant® based on severity\n\nocular toxicity\nrybrevant® can cause ocular toxicity including keratitis dry eye symptoms conjunctival redness blurred vision visual impairment ocular itching and uveitis\n\nrybrevant® with carboplatin and pemetrexed\n\nbased on the safety population rybrevant® in combination with carboplatin and pemetrexed can cause ocular toxicity including blepharitis dry eye conjunctival redness blurred vision and eye pruritus all events were grade \n\nrybrevant® as a single agent\n\nbased on the safety population keratitis occurred in and uveitis occurred in of patients treated with rybrevant® all events were grade promptly refer patients presenting with eye symptoms to an ophthalmologist withhold dose reduce or permanently discontinue rybrevant® based on severity\n\nembryofetal toxicity\nbased on its mechanism of action and findings from animal models rybrevant® can cause fetal harm when administered to a pregnant woman advise females of reproductive potential of the potential risk to the fetus advise female patients of reproductive potential to use effective contraception during treatment and for months after the last dose of rybrevant®\n\nadverse reactions\nrybrevant® with carboplatin and pemetrexed\n\nfor the patients in the papillon clinical trial who received rybrevant® in combination with carboplatin and pemetrexed the most common adverse reactions were rash nail toxicity stomatitis infusionrelated reaction fatigue edema constipation decreased appetite nausea covid diarrhea and vomiting the most common grade to laboratory abnormalities were decreased albumin increased alanine aminotransferase increased gammaglutamyl transferase decreased sodium decreased potassium decreased magnesium and decreases in white blood cells hemoglobin neutrophils platelets and lymphocytes \n\nserious adverse reactions occurred in of patients who received rybrevant® in combination with carboplatin and pemetrexed serious adverse reactions in of patients included rash pneumonia ild pulmonary embolism vomiting and covid fatal adverse reactions occurred in patients due to pneumonia cerebrovascular accident cardiorespiratory arrest covid sepsis and death not otherwise specified\n\nrybrevant® as a single agent\n\nfor the patients in the chrysalis clinical trial who received rybrevant® as a single agent the most common adverse reactions were rash irr paronychia musculoskeletal pain dyspnea nausea fatigue edema stomatitis cough constipation and vomiting the most common grade to laboratory abnormalities were decreased lymphocytes decreased albumin decreased phosphate decreased potassium increased alkaline phosphatase increased glucose increased gammaglutamyl transferase and decreased sodium \n\nserious adverse reactions occurred in of patients who received rybrevant® serious adverse reactions in of patients included pulmonary embolism pneumonitisild dyspnea musculoskeletal pain pneumonia and muscular weakness fatal adverse reactions occurred in patients due to pneumonia and patient due to sudden death\n\nplease read the full prescribing information for rybrevant®\n\nabout johnson johnson\nat johnson johnson we believe health is everything our strength in healthcare innovation empowers us to build a world where complex diseases are prevented treated and cured where treatments are smarter and less invasive and solutions are personal through our expertise in innovative medicine and medtech we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity learn more at or at follow us at janssenus and jnjinnovmed janssen research development llc and janssen biotech inc are both johnson johnson companies\n\ncautions concerning forwardlooking statements\nthis press release contains “forwardlooking statements” as defined in the private securities litigation reform act of regarding product development and the potential benefits and treatment impact of rybrevant® amivantamabvmjw and lazertinib the reader is cautioned not to rely on these forwardlooking statements these statements are based on current expectations of future events if underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize actual results could vary materially from the expectations and projections of janssen research development llc janssen biotech inc and johnson johnson risks and uncertainties include but are not limited to challenges and uncertainties inherent in product research and development including the uncertainty of clinical success and of obtaining regulatory approvals uncertainty of commercial success competition including technological advances new products and patents attained by competitors challenges to patents changes in behavior and spending patterns of purchasers of health care products and services changes to applicable laws and regulations including global health care reforms and trends toward health care cost containment a further list and descriptions of these risks uncertainties and other factors can be found in johnson johnson’s annual report on form k for the fiscal year ended january including in the sections captioned “cautionary note regarding forwardlooking statements” and “item a risk factors” and in johnson johnson’s subsequent quarterly reports on form q and other filings with the securities and exchange commission copies of these filings are available online at or on request from johnson johnson none of janssen research development llc janssen biotech inc and johnson johnson undertakes to update any forwardlooking statement as a result of new information or future events or developments'
'submissions supported by data from landmark phase mariposa study which showed statistically significant and clinically meaningful improvement in progressionfree survival in patients with egfrmutated advanced nsclc treated with rybrevant® plus lazertinib versus osimertinib\n\nraritan nj dec prnewswire johnson johnson announced today the submission of a supplemental biologics license application sbla to the us food and drug administration fda together with a new drug application nda seeking the approval of rybrevant® amivantamabvmjw in combination with lazertinib for the firstline treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer nsclc with epidermal growth factor receptor egfr exon deletions or lr substitution mutations as detected by an fdaapproved test based on the phase mariposa study this marks the third submission from the rybrevant® clinical development program in four months following sbla submissions for mariposa and papillon\n\nthe combination of rybrevant® and lazertinib demonstrated statistically significant and clinically meaningful improvement in progressionfree survival compared to osimertinib in patients with previously untreated egfrmutated nsclc this remains an area of high unmet need as patients often experience treatment resistance and disease progression on currently available therapies said kiran patel md vice president clinical development solid tumors johnson johnson innovative medicine we believe this targeted chemotherapyfree regimen may have the potential to transform the treatment of egfrmutated nsclc and we look forward to working with the fda in review of these applications \n\nthese applications are supported by data from the phase mariposa nct study evaluating the efficacy and safety of rybrevant® in combination with lazertinib versus osimertinib and versus lazertinib alone in firstline treatment of patients with locally advanced or metastatic nsclc with egfr exdel or lr substitution mutations results from the mariposa study were recently presented in a presidential symposium at the european society of medical oncology esmo congress abstract lba\n\nabout the mariposa study\n\nmariposa nct which enrolled patients is a randomized phase study evaluating rybrevant® amivantamabvmjw a bispecific antibody targeting egfr and mesenchymalepithelial transition met in combination with lazertinib an oral thirdgeneration epidermal growth factor receptor egfr tyrosine kinase inhibitor tki versus osimertinib and versus lazertinib alone in firstline treatment of patients with locally advanced or metastatic nsclc with egfr exdel or lr substitution mutations the primary endpoint of the study is progressionfree survival pfs using recist v guidelines as assessed by blinded independent central review bicr secondary endpoints include os orr dor second progressionfree survival pfs and intracranial pfs\n\nthe mariposa study required all patients to have serial brain imaging with mris in order to detect or monitor brain metastases a measure not implemented in most prior studies for egfrmutated nsclc the primary endpoint of pfs in mariposa included these central nervous system cns events detected by serial brain mris extracranial pfs which may more closely approximate what would be seen in other trials was also explored in mariposa \n\nabout rybrevant® \n\nrybrevant® amivantamabvmjw a fullyhuman bispecific antibody targeting egfr and met with immune celldirecting activity received accelerated approval by the us food and drug administration fda in may for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon insertion mutations as detected by an fdaapproved test whose disease has progressed on or after platinumbased chemotherapy this indication is approved under accelerated approval based on orr and dor continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials rybrevant® has also received approval from health authorities in europe as well as other markets around the world the supplemental biologics license application sbla johnson johnson submitted to the us fda for rybrevant® in combination with chemotherapy carboplatinpemetrexed for the firstline treatment of patients with nsclc with egfr exon insertion mutations has been granted priority review in october a type ii extension of indication application was submitted to the european medicines agency ema seeking approval of rybrevant® for this indication in november johnson johnson submitted an sbla to the us fda for rybrevant® in combination with chemotherapy for the treatment of patients with egfrmutated nsclc who progressed on or after osimertinib a type ii extension of indication application was also submitted to the ema seeking the approval of rybrevant® for this indication\n\nthe nccn clinical practice guidelines in oncology nccn guidelines® for nsclc‡ prefer nextgeneration sequencing–based strategies over polymerase chain reaction–based approaches for the detection of egfr exon insertion variants and include amivantamabvmjw rybrevant® as a subsequent therapy option with a category a recommendation for patients that have progressed on or after platinumbased chemotherapy with or without immunotherapy and have egfr exon insertion mutationpositive advanced nsclc§\n\nin addition to the phase mariposa study rybrevant® is being studied in multiple clinical trials in nsclc including\n\nthe phase mariposa nct study evaluating the efficacy and safety of rybrevant® and chemotherapy in patients with locally advanced or metastatic egfr exdel or lr substitution nsclc who had disease progression on or after treatment with osimertinib data for this randomized phase study presented at the esmo congress demonstrated statistically significant and clinically meaningful improvement in pfs in patients receiving rybrevant® plus chemotherapy with and without lazertinib versus chemotherapy\nthe phase papillon nct study assessing rybrevant® in combination with carboplatinpemetrexed versus carboplatinpemetrexed in the firstline treatment of patients with advanced or metastatic nsclc with egfr exon insertion mutations data for this randomized phase study presented at the esmo congress demonstrated statistically significant and clinically meaningful improvement in pfs in patients receiving rybrevant® versus chemotherapy\nthe phase chrysalis nct study evaluating rybrevant® in participants with advanced nsclc\nthe phase b chrysalis nct study evaluating rybrevant® in combination with lazertinib and lazertinib as a monotherapy in patients with advanced nsclc with egfr mutations\nthe phase paloma nct study assessing the feasibility of subcutaneous sc administration of amivantamab based on safety and pharmacokinetics and to determine a dose dose regimen and formulation for amivantamab sc delivery\nthe phase paloma nct study assessing subcutaneous amivantamab in participants with advanced or metastatic solid tumors including egfrmutated nsclc\nthe phase paloma nct study assessing lazertinib with subcutaneous amivantamab compared to intravenous amivantamab in participants with egfrmutated advanced or metastatic nsclc\nthe phase metalmark nct study assessing rybrevant® and capmatinib combination therapy in locally advanced or metastatic nsclc\nthe phase polydamas nct study assessing rybrevant® and cetrelimab combination therapy in locally advanced or metastatic nsclc\nthe phase skippirr study nct exploring how to decrease the incidence andor severity of firstdose infusionrelated reactions with rybrevant® in combination with lazertinib in relapsed or refractory egfrmutated advanced or metastatic nsclc\nthe phase cocoon study nct will evaluate enhanced dermatological care to reduce rash and paronychia in patients with egfrmutated nsclc treated firstline with amivantamab plus lazertinib\nfor more information visit \n\nabout lazertinib\n\nin janssen biotech inc entered into a license and collaboration agreement with yuhan corporation for the development of lazertinib lazertinib is an oral thirdgeneration brainpenetrant egfr tki that targets both the tm mutation and activating egfr mutations while sparing wildtype egfr an analysis of the efficacy and safety of lazertinib from the phase laser study was published in the journal of clinical oncology in \n\nabout nonsmall cell lung cancer\n\nworldwide lung cancer is one of the most common cancers with nsclc making up to percent of all lung cancer cases the main subtypes of nsclc are adenocarcinoma squamous cell carcinoma and large cell carcinoma among the most common driver mutations in nsclc are alterations in egfr which is a receptor tyrosine kinase controlling cell growth and division egfr mutations are present in to percent of western patients with nsclc with adenocarcinoma histology and occur in to percent of asian patients egfr exdel or egfr lr mutations are the most common egfr mutations the fiveyear survival rate for all people with advanced nsclc and egfr mutations treated with egfr tkis is less than percent patients with egfr exdel or lr mutations have a realworld fiveyear os of percent\n\nrybrevant® important safety information\n\nwarnings and precautions \n\ninfusionrelated reactions \n\nrybrevant® can cause infusionrelated reactions irr signs and symptoms of irr include dyspnea flushing fever chills nausea chest discomfort hypotension and vomiting\n\nbased on the safety population irr occurred in of patients treated with rybrevant® among patients receiving treatment on week day experienced an irr while the incidence of irr was with the day infusion with the week infusion and cumulatively with subsequent infusions of the reported irrs were grade were grade and were grade the median time to onset was hour range to hours after start of infusion the incidence of infusion modifications due to irr was and of patients permanently discontinued rybrevant® due to irr\n\npremedicate with antihistamines antipyretics and glucocorticoids and infuse rybrevant® as recommended administer rybrevant® via a peripheral line on week and week monitor patients for any signs and symptoms of infusion reactions during rybrevant® infusion in a setting where cardiopulmonary resuscitation medication and equipment are available interrupt infusion if irr is suspected reduce the infusion rate or permanently discontinue rybrevant® based on severity\n\ninterstitial lung diseasepneumonitis\n\nrybrevant® can cause interstitial lung disease ildpneumonitis based on the safety population ildpneumonitis occurred in of patients treated with rybrevant® with of patients experiencing grade ildpneumonitis three patients discontinued rybrevant® due to ildpneumonitis \n\nmonitor patients for new or worsening symptoms indicative of ildpneumonitis eg dyspnea cough fever immediately withhold rybrevant® in patients with suspected ildpneumonitis and permanently discontinue if ildpneumonitis is confirmed\n\ndermatologic adverse reactions\n\nrybrevant® can cause rash including dermatitis acneiform pruritus and dry skin based on the safety population rash occurred in of patients treated with rybrevant® including grade rash in of patients the median time to onset of rash was days range to days rash leading to dose reduction occurred in of patients and rybrevant® was permanently discontinued due to rash in of patients\n\ntoxic epidermal necrolysis occurred in one patient treated with rybrevant®\n\ninstruct patients to limit sun exposure during and for months after treatment with rybrevant® advise patients to wear protective clothing and use broad spectrum uvauvb sunscreen alcoholfree emollient cream is recommended for dry skin\n\nif skin reactions develop start topical corticosteroids and topical andor oral antibiotics for grade reactions add oral steroids and consider dermatologic consultation promptly refer patients presenting with severe rash atypical appearance or distribution or lack of improvement within weeks to a dermatologist withhold dose reduce or permanently discontinue rybrevant® based on severity\n\nocular toxicity\n\nrybrevant® can cause ocular toxicity including keratitis dry eye symptoms conjunctival redness blurred vision visual impairment ocular itching and uveitis based on the safety population keratitis occurred in and uveitis occurred in of patients treated with rybrevant® all events were grade promptly refer patients presenting with eye symptoms to an ophthalmologist withhold dose reduce or permanently discontinue rybrevant® based on severity\n\nembryofetal toxicity\n\nbased on its mechanism of action and findings from animal models rybrevant® can cause fetal harm when administered to a pregnant woman advise females of reproductive potential of the potential risk to the fetus advise female patients of reproductive potential to use effective contraception during treatment and for months after the final dose of rybrevant®\n\nadverse reactions\n\nthe most common adverse reactions were rash irr paronychia musculoskeletal pain dyspnea nausea fatigue edema stomatitis cough constipation and vomiting the most common grade to laboratory abnormalities were decreased lymphocytes decreased albumin decreased phosphate decreased potassium increased alkaline phosphatase increased glucose increased gammaglutamyl transferase and decreased sodium \n\nplease read the full prescribing information for rybrevant® \n\nabout johnson johnson\n\nat johnson johnson we believe health is everything our strength in healthcare innovation empowers us to build a world where complex diseases are prevented treated and cured where treatments are smarter and less invasive and solutions are personal through our expertise in innovative medicine and medtech we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity learn more at or at follow us at janssenus and jnjinnovmed janssen research development llc and janssen biotech inc are both johnson johnson companies\n\ncautions concerning forwardlooking statements\n\nthis press release contains forwardlooking statements as defined in the private securities litigation reform act of regarding product development and the potential benefits and treatment impact of rybrevant® amivantamabvmjw and lazertinib the reader is cautioned not to rely on these forwardlooking statements these statements are based on current expectations of future events if underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize actual results could vary materially from the expectations and projections of janssen research development llc janssen biotech inc and johnson johnson risks and uncertainties include but are not limited to challenges and uncertainties inherent in product research and development including the uncertainty of clinical success and of obtaining regulatory approvals uncertainty of commercial success competition including technological advances new products and patents attained by competitors challenges to patents changes in behavior and spending patterns of purchasers of health care products and services changes to applicable laws and regulations including global health care reforms and trends toward health care cost containment a further list and descriptions of these risks uncertainties and other factors can be found in johnson johnsons annual report on form k for the fiscal year ended january including in the sections captioned cautionary note regarding forwardlooking statements and item a risk factors and in johnson johnsons subsequent quarterly reports on form q and other filings with the securities and exchange commission copies of these filings are available online at or on request from johnson johnson none of janssen research development llc janssen biotech inc and johnson johnson undertakes to update any forwardlooking statement as a result of new information or future events or developments\n\nrecist v refers to response evaluation criteria in solid tumors which is a standard way to measure how well solid tumors respond to treatment and is based on whether tumors shrink stay the same or get bigger\n\n‡the nccn content does not constitute medical advice and should not be used in place of seeking professional medical advice diagnosis or treatment by licensed practitioners nccn makes no representations or warranties and explicitly disclaims the appropriateness or applicability of the nccn content to any specific patients care or treatment\n\n§see the nccn guidelines for detailed recommendations including other treatment options\n\nthe nccn guidelines for nsclc provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories'

'please join us for the highly anticipated eighth annual blue jacket fashion show a unique event founded by fashion designer frederick anderson benefitting zero prostate cancer sponsored by johnson johnson this exceptional gathering seamlessly blends the realms of fashion entertainment sports healthcare and media to openly address the critical issue of prostate cancer\n\nsupport for this event helps bridge the gap between racial and health disparities in prostate cancer among black men and underserved communities\n\nwith a specific emphasis on tackling racial disparities and underserved communities the blue jacket fashion show is more than just a display of style it’s a platform for meaningful conversations for a disease that impacts in men as part of this annual event there will be free screenings held in three new york city locations as well as a fashion show afterparty zero prostate cancer is proud to be the blue jackets charity partner\n\nluis a miranda jr j harrison ghee marcus samuelsson billy porter holly robinson peete don lemon nigel barker and many other celebrities who are passionate about raising awareness about prostate cancer will grace the runway this year \n\nthe blue jacket fashion show takes place on thursday february at moonlight studios in new york city you’re invited to join the fun and watch the entire blue jacket fashion show live stream right here on zeros youtube channel\n\nfeatured on the blue carpet\nthe worlds of fashion entertainment sports healthcare and media unite again for the blue jacket fashion show many have been walking the catwalk since the event launched in but there are also some exciting new faces this year \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nsponsored by\njohnson johnson logo'
'the us house of representatives committee on china has asked the fbi and the intelligence community for a briefing on genscript biotechnology co and three subsidiaries to determine if the chinese communist party has influence over their operations\n\nin a letter dated may to the fbi and the us office of the director of national intelligence committee chair john moolenaar and ranking member raja krishnamoorthi said genscripts work with us companies and the government raises concerns about the intellectual property of us firms and could help improve chinas biotech capabilities\n\nthe three subsidiaries cited in the letter are bestzyme legend biotech and probio\n\n\ndrugmaker legend partnered with johnson johnson in to develop cancer cell therapy carvykti they sold million of the drug last year and expect sales to eventually top billion a year\n\na spokesperson for genscript said they were founded in new jersey and do not take direction from any government they added that they looked forward to speaking with the house committee\n\nlegend and jj did not immediately respond to requests for comment nor did the other subsidiaries genscript is a pharmaceutical research and manufacturing service provider with over customers in over countries and sales manufacturing and research and development presence in china the us europe and the asia pacific according to its website\n\nthe lawmakers interest in genscript comes two weeks after another committee in the house approved a bill that would restrict business with chinas wuxi apptec wuxi biologics bgi mgi and complete genomics and other possible biotech companies of concern\n\nthe bill must still get through the full house and senate before president joe biden could sign it into law but if passed it would push us pharmaceutical and healthcare companies to lessen their reliance on chinese research and manufacturing\n\ngenscripts role as a contract development and manufacturing organization including services such as the production of custom gene synthesis for companies and us government entities raises concerns about potential risks to the intellectual property of us firms and genscripts broader role in advancing the prcs china biotech capabilities the letter said \n\n© thomsonreuters all rights reserved'
'takeda pharmaceutical has secured an option on an alzheimer’s disease immunotherapy from ac immune that is on track to report its first phase data later this quarter exercising the option would make takeda responsible for phase testing of the therapy putting ac immune in line for up to billion in milestone payments\n\nalzheimer’s disease can be treated with antibody drugs that reduce levels of amyloid beta protein in the brain clinicalstage biotech company ac immune is developing a novel therapy that sparks the immune system to clear away amyloid plaque and takeda pharmaceutical sees enough promise in this approach to commit million for the opportunity to pick up this experimental therapy\n\nthe ac immune drug codenamed aci is currently being evaluated in the phase portion of a phase b study under the deal terms announced monday takeda’s upfront payment gives it an exclusive option to license global rights to this immunotherapy\n\naci is an immunogenic peptide that is presented to the immune system’s b cells in a way that mimics the pathological form of amyloid beta this presentation is intended to spark activity from antibodies that bind to pathological forms of the protein in preclinical research lausanne switzerlandbased ac immune has reported that the drug led to higher blood levels of immunoglobulin g antibodies that were associated with reduction in amyloid plaque in tests in monkeys ac immune reported a favorable safety profile for the drug\n\nac immune is responsible for completing the placebocontrolled phase b study which is evaluating for aci in patients with early alzheimer’s the study is also testing the immunotherapy as a treatment for patients with down syndrome under the takeda agreement the japanese pharmaceutical giant may exercise its option after it receives predefined clinical data on the first three alzheimer’s patient cohorts from the ongoing study ac immune said in a regulatory filing the first phase data on amyloid plaque reduction after six months of treatment will be reported in the current quarter potentially paving the way for phase testing ac immune said monday in its report of financial results for the first quarter of \n\n“we believe the maximum impact of aci can best be realized by partnering with takeda at this critical juncture in its development which will help us move rapidly into phase ” ac immune ceo andrea pfeifer said in a prepared statement “this agreement allows us to leverage the developmental expertise strategic vision and financial capacity of an accomplished organization that has demonstrated its ability to execute the type of comprehensive global program required for phase trials in alzheimer’s disease while allowing us to focus on completing phase b development and accelerating our efforts to replicate this success with enhanced funding for our earlystage pipeline”\n\nupdated to add the following three paragraphs with analyst commentary an antiamyloid beta or “abeta” approach already has partial validation from the fda approval of the amyloid plaque antibody busting drug leqembi from eisai as well as donanemab an eli lilly drug still under regulatory review leerink partners analyst marc goodman wrote in a march research note but safety could be a key differentiator for an alzheimer’s immunotherapy antibody drugs developed for the disease introduce the risk of amyloidrelating imaging abnormalities aria brain bleeding and swelling that is a known adverse effect of this class of therapies an earlier formulation of ac immune’s therapy yielded mixed phase data while the results showed favorable safety with no signs of aria the immune response was “suboptimal” goodman said\n\naci is a new formulation incorporating changes intended to boost the immune response goodman said translation of immune response to amyloid beta clearance andor clinical benefit remains a key question also active immunotherapy may take longer to show an effect compared with antibody drugs he added while those questions remain unanswered so far the takeda deal is positive news for ac immune goodman wrote in a monday research note\n\nonce again management has executed on a significant partnership with a big pharma company to develop an asset that has received minimal value in the stock confirming our longterm thesis that this management team can leverage its two proprietary drug discovery platforms and diversified pipeline to drive value” goodman said\n\nthe agreement makes ac immune eligible for up to billion in milestone payments which includes an option exercise fee in the lowtomidhundred millions of dollars according to the regulatory filing after exercising that option takeda will be responsible for clinical development of the alzheimer’s drug takeda will also handle regulatory submissions as well as commercialization if the drug is approved ac immune will receive royalties from takeda’s sales of the immunotherapy\n\naci would give takeda another opportunity to address alzheimer’s but with a drug candidate that has been derisked with clinical data the company previously partnered with denali therapeutics on the development of an antibody engineered to penetrate the brain to hit and activate a target called trem last august the two companies announced they would discontinue clinical development of this alzheimer’s drug after safety signals emerged in phase testing takeda also has a research collaboration with cure network dolby acceleration partners focused on developing small molecules that target tau in alzheimer’s and other brain disorders\n\nac immune has other alliances in alzheimer’s its antitau immunotherapy aci is currently in midstage clinical development under a partnership with johnson johnson subsidiary janssen pharmaceuticals a tau aggregation inhibitor is in preclinical development under a partnership with eli lilly two ac immune antibodies semorinemab and crenezumab were partnered with roche’s genentech division but after disappointing clinical trial results genentech terminated the alliance early this year returning to ac immune rights to both antibodies'

Evaluation

Metrics

Label	Accuracy
all	0.4310

Uses

Direct Use for Inference

First install the SetFit library:

pip install setfit

Then you can load this model and run inference.

python

from setfit import SetFitModel

# Download from the 🤗 Hub
model = SetFitModel.from_pretrained("csong97/setfit-jnj-relevancy")
# Run inference
preds = model("johnson  johnson shares positive results for tar in highrisk bladder cancer  pmlive

                                                                                     

 

 

 

 

   advertise
   subscribe
   contact
   publications
       pme
       pme supplements
       communique
       t

   advertise
   subscribe
   contact
   publications
       pme
       pme supplements
       communique
       t

   follow follow on facebook
   follow follow on x
   follow follow on linkedin
   follow follow on rss

  pharmafile logo

  t  cover

  diversity equity and inclusion

  communiqué  cover 

   pmlive

  t  cover

  diversity equity and inclusion

  communiqué  cover 

   pmlive

  t  cover

  diversity equity and inclusion

  communiqué  cover 

   pmlive

   
   news
       research
       sales
       regulatory
       healthcare
       marketing
   intelligence
       intelligence
       webinars
       podcasts
       digital handbook
       orphan drugs  rare diseases
       glossary
       healthcare advertising gallery
   thought leadership
   appointments
   awards
   blogs
       digital intelligence
       smart thinking
       darwin’s medicine
   webinars
   t
       top  overall
       smaller agencies
       independent agencies
       young agencies
       uk focused agencies
       about t
   pmhub
       company profiles
       press releases
       white papers and resources
       videos and podcasts
       pmhub login
       add your company
   jobs
   pme
   
       search
        
        more results
        
       advanced search
        

johnson  johnson shares positive results for tar in highrisk bladder cancer


more than  cases of bladder cancer are diagnosed in the us every year

   pmlive

johnson  johnson jj has shared promising results for its investigational bladder cancer treatment approach tar at this year’s american urological association annual meeting

more than  people are diagnosed with bladder cancer in the us every year with nonmuscleinvasive bladder cancer nmibc accounting for up to  of all newly diagnosed cases

radical cystectomy the removal of the bladder and nearby structures and organs is currently recommended for nmibc patients who fail standardofcare bacillus calmetteguérin bcg immunotherapy however as nmibc usually affects older patients many may be unwilling or unfit to undergo this procedure

tar is an investigational targeted releasing system which enables the controlled release of the chemotherapy drug gemcitabine into the bladder this increases the amount of time the drug delivery system spends in the bladder and sustains local drug exposure according to jj

cohort two of the phase b sunrise trial has been evaluating tar as a monotherapy in patients with bcgunresponsive highrisk nmibc with carcinoma in situ who are ineligible for or decline radical cystectomy

results demonstrated a centrally confirmed complete response cr rate of  with  of crs achieved at the first disease assessment at week  and four of five patients who have completed two years of treatment remaining in cr

the estimated oneyear duration of response rate is  with median followup in responders of  weeks additionally  remained in cr at the data cutoff in january and none of the responders progressed to muscleinvasive bladder cancer or metastasis

“the high cr rate and durability of these responses observed in patients treated with tar underscores the potential of this treatment approach for patients with bcgunresponsive highrisk nmibc” said presenting author joseph jacob department of urology at upstate medical university

sunrise is also evaluating tar which has already been granted breakthrough therapy designation by the us food and drug administration in combination with the investigational antipd monoclonal antibody cetrelimab or cetrelimab alone in the same patient population

christopher cutie vice president disease area leader bladder cancer jj innovative medicine said “these results reinforce the potential of tar to transform the treatment landscape and our ongoing dedication to address unmet needs for patients facing this challenging disease”

article by emily kimber

th may 

from research

johnson  johnson  nonmuscleinvasive bladder cancer  oncology  sunrise  tar

 

 

subscribe to our email news alerts

 latest jobs from pharmarole

account specialist  respiratory  kent  medway account specialist  respiratory  kent  medway

territory sales manager  ostomy care  wales south mids territory sales manager  ostomy care  wales south mids

key account manager  urology  east anglia beds  bucks key account manager  urology  east anglia beds  bucks

territory sales manager  north london  east anglia territory sales manager  north london  east anglia

integrated care specialist  north  west yorkshire integrated care specialist  north  west yorkshire

territory sales manager  ostomy care  wales south mids territory sales manager  ostomy care  wales south mids

 

 

 

 latest content

   novo nordisk’s semaglutide approved by mhra to prevent cardiovascular event risk
   nhs figures reveal record number of people in england being diagnosed with dementia
   merck’s investigational rsv monoclonal antibody clesrovimab shown to protect infants
   gsk’s viiv shares positive headtohead results for twodrug hiv regimen dovato
   researchers develop ai model to identify breast cancer stages and progression

 latest intelligence

   the omnichannel wonderland of opportunities
   women in pharma
   dementia – risk factors research and treatment
   collaborating for change in rheumatology
   pharma’s content conundrum

 quick links

   digital handbook
   the gallery
   healthcare glossary
   how to advertise

   orphan drugs and rare dis
   pme supplements
   social media hub
   webinars

 

 

   about us
   privacy
   terms and conditions
   sitemap
   pmgroup worldwide ltd
   subscribeunsubscribe

   about us
   privacy
   terms and conditions
   sitemap
   pmgroup worldwide ltd
   subscribeunsubscribe

                    

 blob

to provide the best experiences we use technologies like cookies to store andor access device information consenting to these technologies will allow us to process data such as browsing behaviour or unique ids on this site not consenting or withdrawing consent may adversely affect certain features and functions privacy policy website terms and conditions

essentialessentialstatisticsstatisticsmarketingmarketing

accept cookiessave settings

x

cookie settings")

Training Details

Training Set Metrics

Training set	Min	Median	Max
Word count	275	1267.35	4278

Label	Training Sample Count
0	10
1	10

Training Hyperparameters

batch_size: (16, 16)
num_epochs: (2, 2)
max_steps: -1
sampling_strategy: oversampling
num_iterations: 20
body_learning_rate: (2e-05, 2e-05)
head_learning_rate: 2e-05
loss: CosineSimilarityLoss
distance_metric: cosine_distance
margin: 0.25
end_to_end: False
use_amp: False
warmup_proportion: 0.1
seed: 42
eval_max_steps: -1
load_best_model_at_end: False

Training Results

Epoch	Step	Training Loss	Validation Loss
0.02	1	0.2562	-
1.0	50	0.0028	-
2.0	100	0.0008	-

Framework Versions

Python: 3.11.0rc1
SetFit: 1.0.3
Sentence Transformers: 2.6.1
Transformers: 4.39.2
PyTorch: 2.2.2+cpu
Datasets: 2.18.0
Tokenizers: 0.15.0

Citation

BibTeX

bibtex

@article{https://doi.org/10.48550/arxiv.2209.11055,
    doi = {10.48550/ARXIV.2209.11055},
    url = {https://arxiv.org/abs/2209.11055},
    author = {Tunstall, Lewis and Reimers, Nils and Jo, Unso Eun Seo and Bates, Luke and Korat, Daniel and Wasserblat, Moshe and Pereg, Oren},
    keywords = {Computation and Language (cs.CL), FOS: Computer and information sciences, FOS: Computer and information sciences},
    title = {Efficient Few-Shot Learning Without Prompts},
    publisher = {arXiv},
    year = {2022},
    copyright = {Creative Commons Attribution 4.0 International}
}